Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047658 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by InterMune.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00047658 is a Phase 2 study that has completed, run by InterMune. The registered enrollment target is 32 participants.
The verdict
NCT00047658, a Phase 2 study, has completed, sponsored by InterMune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Study GIPF-002 is a phase 2 study designed to characterize the biologic and clinical effects of IFN-g 1b. The objective of the Study is to characterize the biologic and clinical effects of IFN-g 1b administered to patients with idiopathic pulmonary fibrosis (IPF). The Study will be conducted at multiple sites and enroll 30 patients with IPF who have failed treatment with corticosteroids.
Interventions
- DRUG Interferon-gamma 1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2001-11 |
| Est. Completion | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047658
The ClinicalTrials.gov registry entry for NCT00047658 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon-gamma 1b is the first listed.
NCT00047658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047658 about?
NCT00047658 is a clinical study titled "A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)". Study GIPF-002 is a phase 2 study designed to characterize the biologic and clinical effects of IFN-g 1b. The objective of the Study is to characterize the biologic and clinical effects of IFN-g 1b administered to patients with idiopathic pulmonary fibrosis (IPF). The Study will be conducted at mult...
What is the current status of trial NCT00047658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2001-11. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00047658?
The interventions under investigation include: Interferon-gamma 1b (DRUG).
Who is sponsoring clinical trial NCT00047658?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.